Indian Expert Dr. A. Ramkishan Appointed by WHO to Advisory Panel

HYDERABAD: Dr A. Ramkishan, deputy drugs controller of India, Central Drugs Standard Control Organization (CDSCO), has been appointed as one of the experts on the advisory panel on biological standardisation for four years by The World Health Organisation (WHO).

Dr Ramkishan who hails from Hyderabad is the first Indian doctor on the committee. He has 25 years of regulatory service in CDSCO which he joined in 1998 as a drug inspector in Mumbai.

A pharmacy graduate from Kakatiya University, Dr Ramkishan has been awarded 35 awards and honours.

Speaking to Deccan Chronicle Dr Ramkishan said, “The opportunity came on the basis of scientific capacity and expertise and experience in the field of pharmaceutical sciences as well as publications and regulatory experience. For the first time a regulator has been chosen on the panel and this is a huge opportunity for me.”

Related Posts

  • Pharma
  • May 10, 2025
  • 76 views
Pharma sector continues to thrive, driven by price-led expansion

The Indian pharmaceutical market continued rising in April 2025, achieving a strong annual growth of 7.8%, with total sales reaching a remarkable Rs 19,711 crore. According to a report by…

  • Pharma
  • May 10, 2025
  • 74 views
TPG to acquire 35% stake in SCHOTT Poonawalla from SII

Mumbai:  SCHOTT Pharma has announced that TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma sector continues to thrive, driven by price-led expansion

Pharma sector continues to thrive, driven by price-led expansion

TPG to acquire 35% stake in SCHOTT Poonawalla from SII

TPG to acquire 35% stake in SCHOTT Poonawalla from SII

Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

Diabetes drug shows promise for treating prostate cancer

Diabetes drug shows promise for treating prostate cancer